Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
about
Targeting DNA Replication Stress for Cancer TherapyAndrogen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisThe prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countriesPredictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcomaAssociation between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells.The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells.Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia.Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.New therapeutic strategies to treat human cancers expressing mutant p53 proteins.Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients
P2860
Q26739923-C9B35587-F6ED-4377-99D9-6BC0BAD22F76Q26823419-DE091435-B485-41FE-8243-A28345161D97Q33826713-2E4B28C4-468D-49C4-A1FB-7C79460F3714Q33917630-16F46789-FD1D-4EA2-9F6D-9FB2F67D9A73Q34489002-0819CDCA-6B7C-46A6-9A96-35DFE497E683Q35155449-A58511C6-14A2-4657-9F98-E0043EDA9D3BQ35695425-D07A3FB0-E931-451A-A5CA-C5AE46FB23C5Q35722508-6A0B36F3-032A-47AC-B062-FE2EE40CFD83Q36110709-54207EDB-DC87-4C55-B1A8-EB42C4471B09Q36490203-EEE36386-49DD-4557-9488-AEAC5385093AQ36717196-FF6BB349-94AF-4009-96F7-A7A5422619CCQ37367870-23F0A292-E71C-4937-B927-8C6727480D99Q37514118-065E724E-E2D3-43D4-AE72-55DCBD267C26Q38427087-E9200769-C590-42B2-A224-F3C20E254E37Q44429695-3CF4640C-1BDF-41A7-A9E7-2AE459481925Q46264415-FF8E3A58-C866-46F3-B61D-2A26D376969CQ47586106-A02C9546-82FD-4C57-A122-71ECED4C2AEBQ48112143-CF6BB6E0-62AD-4C23-8D77-9822E4FF1C5AQ49962911-3662429D-03E5-45B6-BE7C-650ED2B48641Q50860074-E9426076-45A6-4394-A3CA-10912C6A2C45Q55226968-6FA94B0A-11CE-4466-904A-6AD76B4050BAQ58096003-B247B4A7-EFDA-4765-856A-099CA1601B76
P2860
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Triple-negative breast cancer ...... ated late-onset breast cancer.
@ast
Triple-negative breast cancer ...... ated late-onset breast cancer.
@en
type
label
Triple-negative breast cancer ...... ated late-onset breast cancer.
@ast
Triple-negative breast cancer ...... ated late-onset breast cancer.
@en
prefLabel
Triple-negative breast cancer ...... ated late-onset breast cancer.
@ast
Triple-negative breast cancer ...... ated late-onset breast cancer.
@en
P2093
P2860
P356
P1476
Triple-negative breast cancer ...... ated late-onset breast cancer.
@en
P2093
Anthony Rhodes
Cheng-Har Yip
Lai-Meng Looi
Norhashimah Hassan
Nur Aishah Mohd Taib
Sarah Dean
Soo-Hwang Teo
Sze-Yee Phuah
P2860
P2888
P356
10.1186/BCR3347
P577
2012-11-02T00:00:00Z
P5875
P6179
1029639752